BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22877085)

  • 1. Potent and highly selective benzimidazole inhibitors of PI3-kinase delta.
    Murray JM; Sweeney ZK; Chan BK; Balazs M; Bradley E; Castanedo G; Chabot C; Chantry D; Flagella M; Goldstein DM; Kondru R; Lesnick J; Li J; Lucas MC; Nonomiya J; Pang J; Price S; Salphati L; Safina B; Savy PP; Seward EM; Ultsch M; Sutherlin DP
    J Med Chem; 2012 Sep; 55(17):7686-95. PubMed ID: 22877085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2.
    Gianoncelli A; Cozza G; Orzeszko A; Meggio F; Kazimierczuk Z; Pinna LA
    Bioorg Med Chem; 2009 Oct; 17(20):7281-9. PubMed ID: 19748274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity.
    Safina BS; Sweeney ZK; Li J; Chan BK; Bisconte A; Carrera D; Castanedo G; Flagella M; Heald R; Lewis C; Murray JM; Nonomiya J; Pang J; Price S; Reif K; Salphati L; Seward EM; Wei B; Sutherlin DP
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4953-9. PubMed ID: 23867164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors.
    Shin Y; Suchomel J; Cardozo M; Duquette J; He X; Henne K; Hu YL; Kelly RC; McCarter J; McGee LR; Medina JC; Metz D; San Miguel T; Mohn D; Tran T; Vissinga C; Wong S; Wannberg S; Whittington DA; Whoriskey J; Yu G; Zalameda L; Zhang X; Cushing TD
    J Med Chem; 2016 Jan; 59(1):431-47. PubMed ID: 26652588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.
    Sutherlin DP; Baker S; Bisconte A; Blaney PM; Brown A; Chan BK; Chantry D; Castanedo G; DePledge P; Goldsmith P; Goldstein DM; Hancox T; Kaur J; Knowles D; Kondru R; Lesnick J; Lucas MC; Lewis C; Murray J; Nadin AJ; Nonomiya J; Pang J; Pegg N; Price S; Reif K; Safina BS; Salphati L; Staben S; Seward EM; Shuttleworth S; Sohal S; Sweeney ZK; Ultsch M; Waszkowycz B; Wei B
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4296-302. PubMed ID: 22672799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors.
    Hua Z; Huang X; Bregman H; Chakka N; DiMauro EF; Doherty EM; Goldstein J; Gunaydin H; Huang H; Mercede S; Newcomb J; Patel VF; Turci SM; Yan J; Wilson C; Martin MW
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5392-5. PubMed ID: 22877629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.
    Gonzalez-Lopez de Turiso F; Shin Y; Brown M; Cardozo M; Chen Y; Fong D; Hao X; He X; Henne K; Hu YL; Johnson MG; Kohn T; Lohman J; McBride HJ; McGee LR; Medina JC; Metz D; Miner K; Mohn D; Pattaropong V; Seganish J; Simard JL; Wannberg S; Whittington DA; Yu G; Cushing TD
    J Med Chem; 2012 Sep; 55(17):7667-85. PubMed ID: 22876881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases.
    Wang T; Block MA; Cowen S; Davies AM; Devereaux E; Gingipalli L; Johannes J; Larsen NA; Su Q; Tucker JA; Whitston D; Wu J; Zhang HJ; Zinda M; Chuaqui C
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2063-9. PubMed ID: 22305584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
    Bruce I; Akhlaq M; Bloomfield GC; Budd E; Cox B; Cuenoud B; Finan P; Gedeck P; Hatto J; Hayler JF; Head D; Keller T; Kirman L; Leblanc C; Le Grand D; McCarthy C; O'Connor D; Owen C; Oza MS; Pilgrim G; Press NE; Sviridenko L; Whitehead L
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5445-50. PubMed ID: 22863202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of highly potent and selective PI3Kδ inhibitors.
    Marcoux D; Qin LY; Ruan Z; Shi Q; Ruan Q; Weigelt C; Qiu H; Schieven G; Hynes J; Bhide R; Poss M; Tino J
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2849-2853. PubMed ID: 28209465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
    Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.
    Cee VJ; Cheng AC; Romero K; Bellon S; Mohr C; Whittington DA; Bak A; Bready J; Caenepeel S; Coxon A; Deak HL; Fretland J; Gu Y; Hodous BL; Huang X; Kim JL; Lin J; Long AM; Nguyen H; Olivieri PR; Patel VF; Wang L; Zhou Y; Hughes P; Geuns-Meyer S
    Bioorg Med Chem Lett; 2009 Jan; 19(2):424-7. PubMed ID: 19062275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
    Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis.
    Bartok B; Boyle DL; Liu Y; Ren P; Ball ST; Bugbee WD; Rommel C; Firestein GS
    Am J Pathol; 2012 May; 180(5):1906-16. PubMed ID: 22433439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel non-benzimidazole chk2 kinase inhibitors.
    McClure KJ; Huang L; Arienti KL; Axe FU; Brunmark A; Blevitt J; Breitenbucher JG
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1924-8. PubMed ID: 16442290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.
    Safina BS; Baker S; Baumgardner M; Blaney PM; Chan BK; Chen YH; Cartwright MW; Castanedo G; Chabot C; Cheguillaume AJ; Goldsmith P; Goldstein DM; Goyal B; Hancox T; Handa RK; Iyer PS; Kaur J; Kondru R; Kenny JR; Krintel SL; Li J; Lesnick J; Lucas MC; Lewis C; Mukadam S; Murray J; Nadin AJ; Nonomiya J; Padilla F; Palmer WS; Pang J; Pegg N; Price S; Reif K; Salphati L; Savy PA; Seward EM; Shuttleworth S; Sohal S; Sweeney ZK; Tay S; Tivitmahaisoon P; Waszkowycz B; Wei B; Yue Q; Zhang C; Sutherlin DP
    J Med Chem; 2012 Jun; 55(12):5887-900. PubMed ID: 22626259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors.
    Bandarage U; Hare B; Parsons J; Pham L; Marhefka C; Bemis G; Tang Q; Moody CS; Rodems S; Shah S; Adams C; Bravo J; Charonnet E; Savic V; Come JH; Green J
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5191-4. PubMed ID: 19632115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment based discovery of a novel and selective PI3 kinase inhibitor.
    Hughes SJ; Millan DS; Kilty IC; Lewthwaite RA; Mathias JP; O'Reilly MA; Pannifer A; Phelan A; Stühmeier F; Baldock DA; Brown DG
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6586-90. PubMed ID: 21925880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-epsilon kinase.
    Bamborough P; Christopher JA; Cutler GJ; Dickson MC; Mellor GW; Morey JV; Patel CB; Shewchuk LM
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6236-40. PubMed ID: 16997559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.
    Peterson EA; Boezio AA; Andrews PS; Boezio CM; Bush TL; Cheng AC; Choquette D; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Kim JL; Lewis RT; Liu J; Mullady EL; Potashman MH; Romero K; Shaffer PL; Stanton MK; Stellwagen JC; Teffera Y; Yi S; Cai T; La DS
    Bioorg Med Chem Lett; 2012 Aug; 22(15):4967-74. PubMed ID: 22765895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.